Patients with stage IIIB/IV or recurrent squamous NSCLC ( without prior systemic therapy for advanced disease ) received up to six 3-week cycles of chemotherapy ( carboplatin , area under the curve 6 mg/mLmin/paclitaxel , 200 mg/m ) and were randomized 1:1 to receive motesanib 125 mg ( Arm A ) or placebo ( Arm B ) once daily .